SARS-CoV-2 is the novel highly infectious human coronavirus which by May 2020 has infected 3 million and killed more than 200,000 people. Until immunity is induced in large populations throughout the world this coronavirus is likely to become endemic seasonally causing the coronavirus disease 2019 (COVID-19) in millions worldwide. Scientists and drug companies around the world are working hard to develop a vaccine against the disease with at least five candidate vaccines in clinical evaluation and another 71 in preclinical evaluation. The spike protein (SP) of SARS-CoV-2 is the principal target of most these vaccine candidates. Analysis of 5,700 isolates collected between December 2019 and April 2020 revealed only one mutation which was found in more than 1% of currently circulating viruses ¹ . This finding suggests that a single vaccine based on the consensus sequence of highly conserved SP antigen should be efficacious against current global strains.

Human coronaviruses SARS-CoV and SARS-CoV-2 recognize the angiotensin converting enzyme 2 (ACE2) ² as the natural receptor but present a distinct binding interface to ACE2 and a different network of residue-residue contacts. SARS-CoV and SARS-CoV-2 have comparable binding affinity but the SARS-CoV-2–ACE2 complex contains a higher number of contacts, a larger interface area, and decreased interface residue fluctuations relative to SARS-CoV ³ . These suggest that the receptor binding site (RBD)–ACE2 interface of SARS-CoV-2 resembles some properties of antibody-antigen interactions, which allow the accelerated evolution of spike protein (SP) binding to the ACE2 receptor, similar to the rapid evolution along the antibody-antigen affinity maturation process ³ . This opens the question about the effectiveness of the vaccine against SARS-CoV with mutations, which modulate its interaction with the receptor.

Previously, a novel bioinformatics approach for assessment of the effectiveness of the seasonal influenza vaccine was proposed ⁴ . This approach, which is based on electronic biology, was successfully used for the prediction of the influenza vaccine effectiveness for two successive flu seasons ^{5, 6} . Here, this approach was used for the assessment of the effectiveness of the COVID-19 vaccine. This analysis showed that mutation D614G, which spreads globally, and which is present in >50% of all circulating viruses, could significantly decrease the effectiveness of the COVID-19 vaccine.

In Figure 2a, we show the ISM-based phylogenetic tree for mutant SP1 from SARS-CoV-2. These SP1 are grouped in two separate clusters, A and B, that, according to the informational spectrum (IS) concept, have different interacting and immunological profiles ^{13– 17} . There is no difference between the analyzed SP1 in the homology-based phylogenic tree ( Figure 2b). Presented results suggest that most of the analyzed mutants (cluster A) will interact with ACE2 in a similar way as the WT virus. Only five mutations V367F, R408I, G476S, D111N, and D614G (cluster B) could significantly affect the interaction of SP1 with ACE2. Three of these mutations (V367F, R408I, G476S) are located in the RBD of SP.

The previous ISM-based phylogenetic analysis of hemagglutinins from seasonal influenza viruses showed that viruses which are in the same cluster with the vaccine virus are responsive to the seasonal flu vaccine and those viruses which are grouped in the separate clusters are resistant to the vaccine. This finding served as a base for the accurate prediction of the efficacy of the flu vaccine several months before the start of the flu season ^{5, 6} . The same approach was also used for the design of antigens for the vaccine against ZIKA virus ^{18, 19} . By analogy, it could be expected that SARS-CoV-2 with mutations V367F, R407I, G476S, D111N and D614G in SP are resistant to the COVID-19 vaccines that are based on the WT SARS-CoV-2.

The D614G mutation frequency is much higher than the others. This mutation was found in 55% of sequences sampled globally as of April 10, 2020 ¹ . The next most frequent mutation is found in only 0.87% of these sequences. A virus carrying the D614G mutation, which had not then been observed among sequences from China, was transmitted in January 2020 to Germany and became dominant in Europe and then globally within two months (found in 55% of sequences) ¹ .

The D614G mutation is located in the middle of one of three epitopes of SP1 ²² . This change of large acidic residue D into small hydrophobic residue G in the middle of the epitope would compromise the binding affinity to antibodies elicited by vaccines with WT SP.

The present results suggest that the highly prevalent D614G mutation in SP, although located outside of the receptor binding site, could decrease the efficacy of the vaccine by modulation of the interaction of SARS-CoV with the ACE2 receptor. In addition, this mutation may cause antigenic drift, resulting in vaccine mismatches which additionally could affect the efficacy of the vaccine. These possible obstacles should be considered for the future development of COVID-19 vaccines. The further ISM-based monitoring of the evolution of SARS-CoV-2 is important for identification of other mutations, which could affect the effectiveness of vaccines against this virus.

All data underlying the results are available as part of the article and no additional source data are required.